June 8, 2021
ARLINGTON, Va. — Healthcare Distribution Alliance (HDA) President and CEO Chester “Chip” Davis, Jr., released a statement in response to the release of key findings from the Biden-Harris Administration 100-day supply chain review.
“While the healthcare supply chain has proven to be resilient in the face of a global pandemic, COVID-19 exposed vulnerabilities that require further coordination, cooperation and collaboration between the government and private sector. HDA and its members appreciate the Biden-Harris Administration’s prioritization and work to strengthen and reinforce our nation’s critical supply chains.
“As outlined in the 100-day review, it will be critical to ensure that steps are taken to reform the Strategic National Stockpile (SNS), improve transparency across the pharmaceutical supply chain, and balance cost implications. HDA members are positioned to support these efforts and have extensive relationships with global and domestic manufacturers, fulfilling 93 percent of all U.S. pharmaceutical sales. HDA members have already been supporting the restructuring of the SNS and are regular participants in pharmaceutical supply chain discussions with both public and private stakeholders. The industry stands ready to further leverage its logistics expertise, capacity and capabilities.
“The healthcare distribution industry has, to date, been integrally engaged in our nation’s response to COVID-19, working with federal, state and local government agencies to distribute medical supplies, PPE, therapeutics and vaccines. HDA’s 37 distributor members continue to work around the clock to increase medical capacity and enhance our national supply of critical medications and products required to fight this pandemic, protect our frontline care providers, and enable treatment for patients.
“We look forward to further partnering with the administration to ensure the safety and resiliency of our healthcare supply chain and providing vital medical supplies to healthcare facilities and patients in communities across the country.”
The Healthcare Distribution Alliance (HDA) represents primary pharmaceutical distributors — the vital link between the nation’s pharmaceutical manufacturers and pharmacies, hospitals, long-term care facilities, clinics and others nationwide. Since 1876, HDA has helped members navigate regulations and innovations to get the right medicines to the right patients at the right time, safely and efficiently. The HDA Research Foundation, HDA’s non-profit charitable foundation, serves the healthcare industry by providing research and education focused on priority healthcare supply chain issues.